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Coronavirus disease 2019 (COVID-19) is a new, emerging
medical challenge worldwide, with those affected showing a
variety of clinical presentations, ranging fromasymptomatic or
mild conditions to critical illness. Patients affected by the
causative virus—severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2)—usually experience cough, fever, dyspnea,
myalgia, less frequently gastrointestinal (GI) manifestations
and, rarely, neurological complications. Coagulopathy is com-
mon among those afflicted and appears to be one of the most
significant adverse prognostic signs.1,2 Coagulopathy results
from concomitant activation of coagulation and fibrinolytic
systems,most likely due to a severe proinflammatory state (i.e.,
the so-called cytokine storm) and/or by viral sepsis that
sometimes leads to consumption of coagulation factors and
decreased platelet count, resulting in thrombohemorrhagic
events.3 In this process, plasmin breaks down fibrin present
in plasma and the bronchoalveolar lavage fluid, as well as
potentially other organs, and leading to excess D-dimer/fibrin
(ogen)degradationproduct (FDP) formation. Thismayalso lead
to reduction in platelet count and increased risk for hemor-
rhage.4 In a systematic review of 6,892 patients and meta-
analysis of 3,496 patients, platelets were low in 22.9% and
D-dimer was high in 34.8%; D-dimer was associated with a
severe clinical course with an odds ratio (OR) of 4.03, and low
platelets with an OR of 1.78.5 Disseminated intravascular
coagulation (DIC) in COVID-19 is accompanied by a significant
decrease of fibrinogen, and a marked increase of FDP and
D-dimer, which are characteristics of DIC with hyperfibrinol-
ysis, whereas the DIC caused by infection is accompanied by
plasminogen activator inhibitor-1 release and suppression of
fibrinolysis. Administration of antiproteasesmay prove benefi-
cial.6 Elevated D-dimer, and FDP, often mildly prolonged pro-
thrombin time and mildly decreased platelet counts were also
reported as common findings by Tang et al, more common and
more profound in severely affected patients.2 Fibrinogen levels
are sometimes lowered, but may instead be elevated, while
activated partial thromboplastin time is sometimes prolonged,
butmay insteadbeshortened,with thesepotentially suggestive
of acute phase events.2,6 Although hypercoagulability and
thrombotic events are common in COVID-19, bleeding may
occur at any time during the course of disease. Several factors
make patients with COVID-19 prone to bleeding, including
thrombocytopenia, hyperfibrinolytic state, consumption of
coagulation factors, and thromboprophylaxis administration
of anticoagulants. A proposed cytokine storm, prolonged tissue
hypoxia, and direct invasion of affected tissues are other
possible causes.2,7,8 Although thrombosis is relatively well
studied in COVID-19, bleeding and bleeding risk appear to be
the forgotten side of this story, most probably due to the less-
fatal consequences; however, hemorrhagic diatheses repre-
sents a significant morbidity and potential cause of death in
COVID-19 in at least in a subset of patients.7,8
Thrombocytopenia
In one early study, about one-third and about half of patients
developed thrombocytopenia and increased D-dimer,
respectively, while among severely affected patients the
rates were around 60%.1 In another recent large-scale retro-
spective study on 1,476 consecutive patients, approximately
20% had thrombocytopenia (< 150 109/L).9 Thosewho died
had a progressive decrease in platelet count, and when the
platelet count was lower the risk of death was higher. For
example, the relative risk of death and themorality ratewere
3.42 (95% confidence interval [CI]: 2.36–4.96), 9.99 (95% CI:
7.16–13.94), and 13.68 (95% CI: 9.89–18.92), and 17.5, 61.2,
and 92.1%, for platelet counts of 100–150, 50–100, and
0–50 109/L, respectively. Of all patients with thrombocy-
topenia, approximately 25% were severely ill, with platelet
count between 0 and 50109/L.9 These patients are at risk of
bleeding, and most guidelines recommend platelet transfu-
sion when their platelet count is between< 30–50 109/L,
for bleeders or for those at high risk of bleeding,
and< 10 109/L, whether bleeding or not.10,11 Therapeutic
response of platelet replacement is lower in patients with
DIC, high fever, or splenomegaly.10 In the setting of COVID-
19, currently lacking randomized clinical trials, there is no
definite guidance on threshold for platelet transfusion.
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In a study of 61 severe intensive care unit (ICU)-treated and
93 severe non-ICU patients, 41% of the former had severe
thrombocytopenia (< 50 109/L), 96% of which had fatal
consequences. Fatal consequences were observed in ICU-
treated nonsurvivors with progressively worsening thrombo-
cytopenia, but thiswas rarely observed in non-ICU severe cases
or ICU-treated survivors. More than 55% of nonsurvivors had a
platelet count less than< 50 109/L, and approximately 20% of
nonsurvivors had a platelet count less than< 10 109/L in the
very late stage of the disease, 2 to 3 days prior to death.
Continuous renal replacement therapy (CRRT) significantly
decreased the platelet count inmore than 80% of CRRT-treated
patients: inapproximately50%,plateletcountwas< 10 109/L
a few days after treatment onset; subsequently bleedingmight
occur in these patients. The overall survival rate was approxi-
mately 6% for patients treated with CRRT.12 Among severely
affected ICU-treated patients, those under low-molecular-
weight heparin (LMWH) therapy had a lower platelet count
than patients not on therapy. ICU-treated patients under
LMWH therapy also had a lower survival rate than those
without heparin. Heparin exposure was considered a risk
factor for progression toward mortality in severe COVID-19
patients.12 In fact the authors found that CRRT, heparin expo-
sure, and significant platelet decrease were risk factors for the
severely ill. Significant heparin-induced thrombocytopenia
(HIT) was observed, both spontaneously and after heparin
exposure, which might contribute to occurrence of severe
thrombocytopenia. Spontaneous HIT may be due to endoge-
nous release of heparin in viral infection.12 Although the
usefulness of heparin-involving anticoagulation therapy in
patients with severe COVID-19 was mentioned by Tang et al,
the risk of HIT should also be considered in these cases.2,12
Critically ill patients with COVID-19 and CRRT have a high
mortality rate,mostly due toHIT. Therefore, careful clinical and
laboratory monitoring should be performed to identify those
with a risk of HIT; in these cases, heparin-involved therapy
should be avoided or discontinued, alternative anticoagulants
suchasdirectoralanticoagulants (DOACs)are recommended.12
Bleeding and Bleeding Risk
Although respiratory failure (70%), multiorgan failure (MOF;
28%), cardiac failure (15%), hemorrhage (6%), and renal
failure (4%) were reported as leading causes of death in
COVID-19 in one study,13 a valuable recent prospective study
revealed that pulmonary embolism (PE) was the direct cause
of death in four (33%), and deep vein thrombosis was
observed in seven (58%).14 In an autopsy report of four
patients, one (25%) had large intra-alveolar hemorrhages
and intra-alveolar fibrin cluster formation.15 Another study
analyzing mortality revealed that 1 (7%) out of 14 patients
died due to GI bleeding.16 It is worth noting, however, that
the patient had lymphoma, thus comorbidities may repre-
sent a part of the risk profile.
Bleeding, when seen as the first presentation in COVID-19,
may lead to misdiagnosis and inappropriate clinical and
laboratory work-up for other viral infections like dengue.17
Fatal GI bleeding and intracranial hemorrhage (ICH) are other
reported forms of severe bleeding.18,19 Although anorexia is
the most common digestive finding (up to 50%) in adults, and
diarrhea is most common in both adults and children (up to
50%) with COVID-19, GI bleeding was observed with a
frequency of 4 to 13.7%, primarily among severely affected
patients, 40% of whom were stool polymerase chain reaction
positive.19,20 It seems that prolonged hypoxia causes cell
necrosis and mucosal injury, leading to ulceration and GI
hemorrhage.12 Focal hemorrhage in the kidney also has been
reported.21 Rare cases of COVID-19 with ICH have been
reported, but further studies are required to clarify this
finding.18 This phenomenon could be attributed to the pro-
posed cytokine storm, and even without direct viral invasion
within the intracranial space could result in breakdown of the
blood–brain barrier.7 A rare case of COVID-19 with immune
thrombocytopenic purpura that developed a subarachnoid
microhemorrhage, while the patient had a platelet count of
2 109/L, has been reported.22 It seems that pathological
immune conditions may be relatively frequent in this disease.
Multiple cerebral infarctions were reported in COVID-19
associatedwith immunoglobulin A antiphospholipid antibod-
ies, although lupus anticoagulant was not present in these
patients, and persistence was not investigated.23 Thus, the
association may not in general hold true.
Thus, overall, the above findings demonstrate that hem-
orrhage and risk of hemorrhage are not necessarily an
infrequent finding in COVID-19, albeit most probably asso-
ciated to contributing factors.
Also, due to a high risk of thrombosis, thromboprophylaxis
with LMWH is recommended by the International Society of
Thrombosis and Hemostasis (ISTH) interim guidance for all
hospitalized patients with COVID-19.24 This recommendation
is based on expert opinion and a few case series. However,
others recommend more aggressive anticoagulant therapy
with unfractionated heparin (UFH), potentially accompanied
by antithrombin supplementation.25,26 Others believe that
administration of LMWH may increase the risk of bleeding
in special situations, such as those otherwise requiring amore
aggressiveanticoagulation, suchasPEthat ismissedbecauseof
primary lung injury by the virus.26 In Japan, nafamostat
mesylate—an inhibitor of plasmin, thrombin, and trypsin—is
used for the management of DIC in COVID-19. Unlike heparin,
nafamostat mesylate does not have hemorrhagic side effects,
even at high doses. Due to its antifibrinolytic actions, the drug
is useful for themanagementofDICwith increasedfibrinolytic
activity. Moreover, it seems that nafamostat mesylate also has
antiviral activity and may potentially be effective in treating
DIC inCOVID-19, but its lowanticoagulant activitymayalso be
a disadvantage.27 Another study shows that thrombosis- and
bleeding-predicting tools are useful in the management of
patients.28 The study assessed the potential usefulness of
Padua prediction score—to predict thrombosis risk—and the
improved bleed risk assessment model—to predict risk of
bleeding—in COVID-19 patients under thromboprophylaxis
with UFH and LMWH. According to the bleeding predicting
tool, nine (6.5%) patients had a high risk of bleeding (improved
score 7), six of whom (67%) experienced hemorrhagic
events during the course of thromboprophylaxis, including
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mild or microscopic hematuria (n: 3), GI bleeding (n: 1),
epistaxis (n: 1), and severehemothorax (n: 1).28More detailed
thromboprophylaxis of patients with COVID-19 and venous
thromboembolism is outside the scope of this work and is
presented elsewhere.28 Anticoagulant therapy is contraindi-
cated for patientswith activebleeding and for thosewith a low
platelet count (according to ISTH guidance< 25 109/L).17 In
COVID-19 patients under treatment with DOACs, the coad-
ministration of antivirals significantly increased the plasma
concentration of DOACs; the trough level of DOAC was 6.14
times higher during hospitalization than before admission.29
To prevent bleeding in such patients, it was suggested that
DOACs be withheld during COVID-19 infection.30
Although clinical presentations in symptomatic children are
relatively similar to adults, in severe cases, septic shock with
irreversiblebleeding and coagulation dysfunctionmayoccur.31
Among the newborns of infected mothers, thrombocytopenia
accompanied by abnormal liver function was observed in two
(20%) and GI bleeding in four (40%). Of the first two patients,
one developed refractory shock, MOF, and DIC, which led to
death in spite of platelet, plasma, and red blood cell trans-
fusions. Another neonate, withGI bleeding andDIC, responded
to intravenous administration of gamma globulin.32
Conclusion
In conclusion, despite its prevalence, COVID-19 remains a
barely understood disease with a high rate of heterogeneous
and disparate clinical pictures. New presentations may be
observed among affected patients, and health care providers
should update their knowledge to prevent severe and fatal
consequences arising from insufficient knowledge. Due to a
high rate of coagulopathy among COVID-19 patients, the risk
of bleeding should always be considered in every case, as
bleeding, although rare, may be one of the first clinical
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